Top in endocrinology: Novel weight loss drug; denosumab vs. alendronate for osteoporosis
Click Here to Manage Email Alerts
Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of receiving BI 456906, a novel glucagon/GLP-1 receptor agonist, during a phase 2 clinical trial, according to a press release.
“The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” Carinne Brouillon, head of human pharma for Boehringer Ingelheim, said in the release.
It was the top story in endocrinology last week.
Another top story covered study results linking Prolia (denosumab, Amgen) to lower fracture risks among postmenopausal women than alendronate when used as a first-line osteoporosis therapy. In the observational, retrospective study, the risk for major osteoporotic fractures continued to decrease over 5 years among women using denosumab vs. those using alendronate.
Read these and more top stories in endocrinology below:
Adults with obesity lose nearly 15% of body weight with glucagon/GLP-1 receptor agonist
A novel glucagon/GLP-1 receptor agonist conferred nearly 15% weight loss at 46 weeks among people with overweight or obesity without type 2 diabetes, according to an industry press release. Read more.
Denosumab bests alendronate as first-line therapy for fracture prevention in osteoporosis
Postmenopausal women with osteoporosis who use denosumab as a first-line therapy have lowers risk for fractures compared with women who use alendronate, according to an industry press release. Read more.
Exposure to EDCs may negatively affect thyroid function, but more research needed
Repeated exposure to endocrine-disrupting chemicals may negatively affect thyroid function, especially for pregnant women and infants, but more research is needed on the synergistic effects, according to a speaker. Read more.
About 45% of teens with obesity improve to overweight or normal weight with semaglutide
Nearly half of adolescents with obesity receiving once-weekly subcutaneous semaglutide achieved overweight or normal weight at 68 weeks, according to data from the STEP TEENS trial presented during the European Congress on Obesity. Read more.
Oral medication boosts annualized height velocity among children with GH deficiency
Children with idiopathic pediatric growth hormone deficiency had an increase in annualized height velocity after 6 months of receiving a daily oral growth hormone therapy, according to a speaker. Read more.